Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026)

Rani Therapeutics Holdings' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $51.9 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 115.04% to $51.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $137.5 million, a 7.09% decrease, with the full-year FY2025 number at $58.6 million, up 60.02% from a year prior.
  • Liabilities and Shareholders Equity came in at $51.9 million for Q1 2026, down from $58.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $115.3 million in Q1 2022, with the low at $10.1 million in Q3 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $63.7 million across 5 years, with a median of $57.9 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 76.71% in 2025 and later soared 115.04% in 2026.
  • Year by year, Liabilities and Shareholders Equity stood at $108.0 million in 2022, then tumbled by 46.39% to $57.9 million in 2023, then plummeted by 36.75% to $36.6 million in 2024, then soared by 60.02% to $58.6 million in 2025, then fell by 11.5% to $51.9 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for RANI at $51.9 million in Q1 2026, $58.6 million in Q4 2025, and $10.1 million in Q3 2025.